A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA in Subjects With Severe Hypertriglyceridemia (EVOLVE II)

Trial Profile

A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA in Subjects With Severe Hypertriglyceridemia (EVOLVE II)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Omega-3 carboxylic acids (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EVOLVE II
  • Sponsors AstraZeneca; Omthera Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 05 Oct 2015 Results published in Boston media release.
    • 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top